Tumor Lipid Signatures Are Descriptive of Acquisition of Therapy Resistance in an Endocrine-Related Breast Cancer Mouse Model
Journal of Proteome Research · 2024
DOI: 10.1021/acs.jproteome.3c00382 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Proteome Research, 2024. Verfasst von Rita Araújo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and CICECO - Aveiro Institute of Materials (CICECO/UA), University of Aveiro, Campus Universitario de Santiago, 3810-193 Avei…. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Lipid Metabolism, Breast Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Regional Development Fund, Agencia Nacional de Promoci?n Cient?fica y Tecnol?gica, Funda??o para a Ci?ncia e a Tecnologia.
Abstract (Originalsprache)
The lipid metabolism adaptations of estrogen and progesterone receptor-positive breast cancer tumors from a mouse syngeneic model are investigated in relation to differences across the transition from hormone-dependent (HD) to hormone-independent (HI) tumor growth and the acquisition of endocrine therapy (ET) resistance (HIR tumors). Results are articulated with reported polar metabolome results to complete a metabolic picture of the above transitions and suggest markers of tumor progression and aggressiveness. Untargeted nuclear magnetic resonance metabolomics was used to analyze tumor and mammary tissue lipid extracts. Tumor progression (HD-HI-HIR) was accompanied by increased nonesterified cholesterol forms and phospholipids (phosphatidylcholine, phosphatidylethanolamine, sphingomyelins, and plasmalogens) and decreased relative contents of triglycerides and fatty acids. Predominating fatty acids became shorter and more saturated on average. These results were consistent with gradually more activated cholesterol synthesis, β-oxidation, and phospholipid biosynthesis to sustain tumor growth, as well as an increase in cholesterol (possibly oxysterol) forms. Particular compound levels and ratios were identified as potential endocrine tumor HD-HI-HIR progression markers, supporting new hypotheses to explain acquired ET resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and CICECO - Aveiro Institute of Materials (CICECO/UA), University of Aveiro, Campus Universitario de Santiago, 3810-193 Aveiro, Portugal.
- IByME - Instituto de Biología y Medicina Experimental, Vuelta de Obligado 2490, C1428 ADN Buenos Aires, Argentina.
- iBIMED - Institute of Biomedicine, Department of Medical Sciences, Universidade de Aveiro, Agra do Crasto, 3810-193 Aveiro, Portugal.
ORCID-Profile: Ana M Gil
Förderung
- European Regional Development Fund
- Agencia Nacional de Promoci?n Cient?fica y Tecnol?gica
- Funda??o para a Ci?ncia e a Tecnologia
Zitieren
APA
Araújo, R., Fabris, V., Lamb, C. A., Elía, A., Lanari, C., Helguero, L. A., & Gil, A. M. (2024). Tumor Lipid Signatures Are Descriptive of Acquisition of Therapy Resistance in an Endocrine-Related Breast Cancer Mouse Model. Journal of Proteome Research. https://doi.org/10.1021/acs.jproteome.3c00382
Vancouver
Araújo R, Fabris V, Lamb CA, Elía A, Lanari C, Helguero LA, et al. Tumor Lipid Signatures Are Descriptive of Acquisition of Therapy Resistance in an Endocrine-Related Breast Cancer Mouse Model. Journal of Proteome Research. 2024. doi:10.1021/acs.jproteome.3c00382
BibTeX
@article{Arajo2024,
author = {Araújo, Rita and Fabris, Victoria and Lamb, Caroline A and Elía, Andrés and Lanari, Claudia and Helguero, Luisa A and Gil, Ana M},
title = {Tumor Lipid Signatures Are Descriptive of Acquisition of Therapy Resistance in an Endocrine-Related Breast Cancer Mouse Model},
journal = {Journal of Proteome Research},
year = {2024},
doi = {10.1021/acs.jproteome.3c00382}
}
EUVIMED